Tempus AI (TEM)

Executive Summary

Tempus AI (NASDAQ: TEM) is a Chicago-based technology company that applies artificial intelligence to advance precision medicine, with an initial and primary focus on oncology. The company has built what it describes as the world's largest library of clinical and molecular data, aggregating de-identified pathology reports, genomic sequences, and treatment outcomes from a network of healthcare partners. Its AI-powered platform organizes this multimodal data to enable pattern discovery and clinical utility, allowing physicians and researchers to make data-driven treatment decisions. Beyond its core data intelligence business, Tempus has expanded into therapeutic development, leveraging its data library to identify and validate new drug targets. The company's pipeline includes seven drug candidates spanning multiple cancer types, with several actively recruiting or ongoing clinical trials. Tempus AI's therapeutic pipeline features notable assets such as A2B530, a bispecific antibody in Phase 1/2 for solid tumors (including pancreatic, lung, and colorectal cancers), with estimated completion in December 2026. Another key candidate is rebecsinib, a menin-MLL inhibitor in Phase 1 for secondary AML and myelofibrosis, which began enrollment in April 2026. The company also has a Phase 1/2 trial for A2B694 combined with A2B543 targeting multiple solid tumors. As Tempus continues to monetize its data platform and advance its internal drug programs, upcoming catalysts include interim data readouts, regulatory updates, and potential partnership announcements that could validate its AI-driven approach and drive value. The company's unique position at the intersection of big data and biotech gives it a differentiated edge, but its success depends on trial execution and market adoption of its precision medicine tools.

Upcoming Catalysts (preview)

• 2026-07Interim data readout from Phase 1/2 trial of A2B530 in solid tumors70% success
• 2027-01Enrollment completion and early data from Phase 1 trial of rebecsinib in secondary AML60% success
• 2026-09Potential partnership or licensing deal for Tempus's data platform or therapeutic assets50% success